Article

Australia OKs sales of Norwood epikeratome

Victoria, Australia—Norwood Devices has received Australia's Therapeutic Goods Administration approval to sell its Centurion SES epikeratome. The device won FDA and CE approval in 2004.

Victoria, Australia-Norwood Devices has received Australia's Therapeutic Goods Administration approval to sell its Centurion SES epikeratome. The device won FDA and CE approval in 2004.

Richard Walmsley, chief executive officer of Norwood Devices, said the potential market in Australia is "significant." However, he sees the single-use disposable separator as the "real revenue and profit generator."

The company expects revenues of $14 million Australian ($10.8 million U.S.) in the 2005 calendar year.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.